Bionovo, Inc. (NASDAQ:BNVI)
| CAPS Rating |
|
|---|---|
| Open | $0.00 |
| Previous Close | $0.14 |
| Daily Range | $0.12 - $0.15 |
| 52-Week Range | $0.13 - $1.03 |
| Market Cap | $6.33M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 0 |
| Average Daily Volume | 0 |
BNVI
VS S&P 500 (SPY)
This ticker is not currently Ratable.
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
BNVI Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
BNVI News and Commentary
- Bionovo Completes Financing, Announces Plan of Action: Is the Worst Over? – SeekingAlpha
- Stocks Mixed at Mid-Day as Improved Unemployment Figures Fail to Boost Sentiment – NASDAQ
- Mid-Day Update: Stocks Mixed Amid Factors Ranging from Stronger Dollar to Boeing Fire – NASDAQ
- Understanding Biopharms: Tom Copeland's interview with the COO of Bionovo, Inc. – Blog at The Motley Fool
- CORRECT(4/20): Bionovo Gets Patent For Breast-Cancer Treatment – SmartMoney
- Bionovo Gets Patent For Breast-Cancer Treatment Method Bezielle – SmartMoney
Related News and Articles
- Illuminating the Way Forward for Genomics – The Motley Fool
- When Passing Your Clinical Trial Isn't Enough – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
- Life Technologies' Sequence of Success – The Motley Fool
- Is Avanir Pharmaceuticals the Perfect Stock? – The Motley Fool
- Can Amgen Convince Docs to Recommend Approval? – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
- Curing Diseases Makes For a Bad Business Model – The Motley Fool
- Idenix Pharmaceuticals Shares Dropped: What You Need to Know – The Motley Fool
- What's Going on With These Biotech Stocks? – The Motley Fool
- Gilead Sciences Shares Surged: What You Need to Know – The Motley Fool
- Has Elan Become the Perfect Stock? – The Motley Fool
RSS Headlines
Fool UK
